公司資料
CVRx 股價、新聞與催化劑
- 股票代碼:
- CVRX
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
2.75 USD (-10.71%)
收盤價
最後更新: 2026年8月17日
144M USD
市值
股價為何變動
As of Aug 17, 2026, CVRX closed down 10.7% at $2.75. No new same-company headline was identified in the current news window.
公司概覽
Cardiovascular Neuromodulation
CVRx is a commercial-stage medical-device company focused on neuromodulation therapies for cardiovascular disease. Its technology electrically activates the body's baroreflex to influence autonomic pathways involved in heart-failure progression.
Barostim Platform
Barostim is the company's implantable therapy for patients with heart failure who remain symptomatic despite guideline-directed medical management. The system is placed by trained physicians and supported through a specialized implanting-center network. CVRx is conducting BENEFIT-HF, a randomized controlled study designed to evaluate Barostim's effect on mortality and heart-failure decompensation in an expanded patient population. The trial complements the company's commercial evidence-generation strategy.
未來催化劑
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。